The Italian generics industry has been growing strongly in the recent years. The market had revenues of over USD 1 billion in 2016 and there is plenty of scope for expansion in the market as the generics volume in the country remains relatively low. By 2021, the market is expected to cross a value of over USD 5 billion.
Aruvian Research presents Analyzing Generics Market in Italy 2017 – a comprehensive coverage of the Italian generic drugs market. Beginning with a sectional description on the global generic industry, the report looks at an overview of the industry, an analysis of the market volume and value, industry segmentation and an industry forecast.
Moving on, we analyze the Generics Industry in Europe through the same parameters.
The Generics Industry in Italy is analyzed through an industry overview which spans the data from 2012 till 2021. An analysis of the industry's value and volume data is included along with an industry segmentation by geography. Industry forecast of the industry is also included.
We also include a Porter’s Five Forces analysis of the Italian Generics Industry. Generics pricing and reimbursement situation in Italy and trends and challenges facing the industry are analyzed.
Analysis of the major industry players in the Italian generics market are analyzed through an analysis of their business segments, a financial analysis and a SWOT analysis. Players analyzed include Mylan NV, Sandoz International, Sanofi and others. This concludes this comprehensive research report from Aruvian Research.
This research report helps you get an insider’s look at the Italian generic industry and helps you understand what the future holds for the industry. Regulatory framework, pricing and reimbursement scenarios, comparison of the Italian market with its regional counterparts, all these data points makes this report an essential resource for analytical purposes.